161 related articles for article (PubMed ID: 31454466)
1. Hepatitis C virus elimination in Indonesia: Epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning.
Trickey A; Hiebert L; Perfect C; Thomas C; El Kaim JL; Vickerman P; Schȕtte C; Hecht R
Liver Int; 2020 Feb; 40(2):286-297. PubMed ID: 31454466
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
[TBL] [Abstract][Full Text] [Related]
4. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan.
Chhatwal J; Chen Q; Wang X; Ayer T; Zhuo Y; Janjua NZ; Kanwal F
JAMA Netw Open; 2019 May; 2(5):e193613. PubMed ID: 31074817
[TBL] [Abstract][Full Text] [Related]
6. Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan.
Zhuo Y; Hayashi T; Chen Q; Aggarwal R; Hutin Y; Chhatwal J
Sci Rep; 2020 Mar; 10(1):4089. PubMed ID: 32139872
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
[TBL] [Abstract][Full Text] [Related]
8. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
11. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
12. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain.
Crespo J; Cuadrado A; Perelló C; Cabezas J; Llerena S; Llorca J; Cedillo S; Llop E; Escudero MD; Hernández Conde M; Puchades L; Redondo C; Fortea JI; Gil de Miguel A; Serra MA; Lazarus JV; Calleja JL
J Viral Hepat; 2020 Apr; 27(4):360-370. PubMed ID: 31755634
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico.
Mooneyhan E; De la Torre Rosas A; Serrano DB; Gamkrelidze I; Sanchez MJ; Kershenobich D; Sereno L; Razavi H
J Viral Hepat; 2023 Jun; 30(6):551-558. PubMed ID: 36890700
[TBL] [Abstract][Full Text] [Related]
15. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
Lim AG; Scott N; Walker JG; Hamid S; Hellard M; Vickerman P
PLoS Med; 2021 Oct; 18(10):e1003818. PubMed ID: 34665815
[TBL] [Abstract][Full Text] [Related]
16. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands.
van Santen DK; de Vos AS; Matser A; Willemse SB; Lindenburg K; Kretzschmar ME; Prins M; de Wit GA
PLoS One; 2016; 11(10):e0163488. PubMed ID: 27711200
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment.
Asker B; Jawad R; Asreah R; Jamal H; Jassem A; Inaya MA; Baker HA; Kozma S; Mansour E; McNamara B; Miller R; Darlington O; McEwan P; Sugrue DM; Jarallah H
Pharmacoeconomics; 2021 Nov; 39(11):1327-1341. PubMed ID: 34396494
[TBL] [Abstract][Full Text] [Related]
19. The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up.
Hecht R; Hiebert L; Spearman WC; Sonderup MW; Guthrie T; Hallett TB; Nayagam S; Razavi H; Soe-Lin S; Vilakazi-Nhlapo K; Pillay Y; Resch S
Health Policy Plan; 2018 May; 33(4):528-538. PubMed ID: 29529282
[TBL] [Abstract][Full Text] [Related]
20. A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and Costs.
Hiebert L; Hecht R; Soe-Lin S; Mohamed R; Shabaruddin FH; Syed Mansor SM; Dahlui M; Azzeri A; McDonald SA
Value Health Reg Issues; 2019 May; 18():112-120. PubMed ID: 30921591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
